Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at Hard-to-Treat ovarian cancer shows promise in trial

NCT ID NCT06682988

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor cells. About 110 participants will receive MIRV on one of two schedules, and a separate group will test a starting dose for those with liver problems. The goal is to find the safest and most effective dosing plan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Both Cohorts * Participants with a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer. * Participants with platinum-resistant disease: * Participants with 1 prior line of platinum-based therapy who have received ≥ 4 cycles of platinum and had a response (complete response (CR) or partial response (PR)) followed by radiological progressive disease (PD) between \> 3 months and ≤ 6 months after the date of the last dose of platinum. * Participants with 2 or 3 prior lines of platinum-based therapy who had radiological PD ≤ 6 months after the date of the last dose of platinum. * Participants with progression diagnosed radiographically on or after their most recent line of therapy. * Participants with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. * Participants with ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the investigator). * Participants with a tumor that is positive for folate receptor alpha (FRα) expression as determined by the Ventana folate receptor 1 (FOLR1) assay (≥ 75% of tumor staining at 2+ intensity). Exclusion Criteria: Both Cohorts * Participants with endometrioid, clear cell, mucinous, or sarcomatous histology; mixed tumors containing any of the above histologies; or low-grade or borderline ovarian tumor. * Participants with primary platinum-refractory disease, defined as disease that did not respond (complete response (CR) or partial response (PR)) or that progressed radiographically within 3 months of the last dose of first-line platinum-containing chemotherapy. * Participants with serious concurrent illness or clinically relevant active infection as outlined in the protocol * Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to randomization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced high-grade epithelial ovarian are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced high-grade epithelial ovarian Advanced high-grade epithelial ovarian cancer Fallopian tube cancers High folate receptor-alpha expression Platinum-resistant Primary peritoneal Primary peritoneal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    52 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Maria Middelares /ID# 272186

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • AZ-Delta /ID# 272250

    RECRUITING

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Addenbrookes Hospital /ID# 272162

    RECRUITING

    Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

  • Algemeen Ziekenhuis klina /ID# 272127

    RECRUITING

    Brasschaat, Antwerpen, 2930, Belgium

  • Allegheny Health Network West Penn Hospital /ID# 272267

    RECRUITING

    Pittsburgh, Pennsylvania, 15244, United States

  • Asan Medical Center /ID# 272130

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • Ballarat Base Hospital /ID# 272240

    RECRUITING

    Ballarat, Victoria, 3350, Australia

  • Baptist Health Lexington /ID# 272211

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku /ID# 272169

    RECRUITING

    Bialystok, Podlaskie Voivodeship, 15-027, Poland

  • Blacktown Hospital /ID# 272182

    RECRUITING

    Blacktown, New South Wales, 2148, Australia

  • CHA Bundang Medical Center /ID# 271590

    RECRUITING

    Seongnam, Gyeonggido, 13496, South Korea

  • CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 272221

    RECRUITING

    Madrid, 28027, Spain

  • Centre Antoine-Lacassagne /ID# 272101

    RECRUITING

    Nice, Provence-Alpes-Côte d'Azur Region, 06189, France

  • Centre Armoricain De Radiothérapie, D'Imagerie Médicale Et D'Oncologie (Cario) /ID# 272201

    RECRUITING

    Plérin, Cotes-d Armor, 22190, France

  • Centre Francois Baclesse /ID# 272204

    RECRUITING

    Caen, Calvados, 14076, France

  • Centre Hospitalier Departemental Vendee (Chd Vendee) /ID# 272174

    RECRUITING

    La Roche-sur-Yon, Vendee, 85925, France

  • Centre Oscar Lambret /ID# 272183

    RECRUITING

    Lille, Nord, 59000, France

  • Clinica Universidad de Navarra - Pamplona /ID# 275742

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Cliniques Universitaires UCL Saint-Luc /ID# 272219

    RECRUITING

    Brussels, Brussels Capital, 1200, Belgium

  • First Physicians Group /ID# 272180

    RECRUITING

    Sarasota, Florida, 34239, United States

  • GH Diaconesses Croix Saint Simon-Hopital De La Croix Saint-Simon /ID# 272179

    RECRUITING

    Paris, 75020, France

  • Gangnam Severance Hospital /ID# 272217

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06273, South Korea

  • HCL - Hopital Lyon Sud /ID# 272178

    RECRUITING

    Pierre-Bénite, Rhone, 69495, France

  • Hospital Clinico Universitario Lozano Blesa /ID# 272165

    RECRUITING

    Zaragoza, 50009, Spain

  • Hospital Clinico Universitario de Valencia /ID# 272218

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca /ID# 272223

    RECRUITING

    El Palmar, Murcia, 30120, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 272121

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Universitario Germans Trias i Pujol /ID# 272216

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Hospital Universitario HM Sanchinarro /ID# 272190

    RECRUITING

    Madrid, 28050, Spain

  • Hospital Universitario Vall de Hebron /ID# 272134

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen del Rocio /ID# 272107

    RECRUITING

    Seville, Sevilla, 41013, Spain

  • Hospital Universitario de Jaén /ID# 272205

    RECRUITING

    Jaén, Jaen, 23007, Spain

  • Icon Cancer Centre Chermside /ID# 272220

    RECRUITING

    Chermside, Queensland, 4032, Australia

  • Institut De Cancérologie De Lorraine Alexis Vautrin /ID# 272147

    RECRUITING

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54519, France

  • Karmanos Cancer Institute - Detroit /ID# 272112

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Keimyung University Dongsan Hospital /ID# 271592

    RECRUITING

    Daegu, Gyeongsangbuk-do, 42601, South Korea

  • Mazowiecki Szpital Wojewodzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. /ID# 271692

    RECRUITING

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • Memorial Hermann Texas Medical Center /ID# 272227

    RECRUITING

    Houston, Texas, 77030, United States

  • Monash Health - Monash Medical Centre - Clayton /ID# 272234

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • National Cancer Center /ID# 272265

    RECRUITING

    Goyang-si, Gyeonggido, 10408, South Korea

  • Newcastle Private Hosptial /ID# 272213

    RECRUITING

    Lambton Heights, New South Wales, 2305, Australia

  • Royal Brisbane and Women's Hospital /ID# 272123

    RECRUITING

    Brisbane, Queensland, 4029, Australia

  • Royal Devon and Exeter Hospital /ID# 272170

    RECRUITING

    Exeter, Devon, EX2 5DW, United Kingdom

  • Samsung Medical Center /ID# 271591

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Bundang Hospital /ID# 271594

    RECRUITING

    Seongnam-si, Gyeonggido, 13620, South Korea

  • Seoul National University Hospital /ID# 272264

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Sir Charles Gairdner Hospital /ID# 272116

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • St. Elizabeth Medical Center - Edgewood /ID# 272113

    RECRUITING

    Edgewood, Kentucky, 41017, United States

  • UMass Memorial Medical Center - Belmont Street /ID# 272122

    RECRUITING

    Worcester, Massachusetts, 01605, United States

  • Universitair Ziekenhuis Leuven /ID# 277350

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

  • University College London Hospital /ID# 272115

    RECRUITING

    London, Greater London, NW1 2BU, United Kingdom

  • Yonsei University Health System Severance Hospital /ID# 271593

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.